AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03658330
Drug: Ketamine + Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).
Trial: NCT03464058
Drug: Rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT01816659
Drug: Metformin ER
RxNorm normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg by mouth once daily, beginning the day after colonoscopy for one week, and then escalation to 1000 mg/day. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
Trial: NCT04533841
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol
Trial: NCT00840645
Drug: YM178
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01884337
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01111981
Drug: Clobetasol Propionate 0.05% Emollient Foam
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol Propionate 0.05% E Foam to be applied to affected area once a day for 16 weeks
Trial: NCT00506051
Drug: ZD6474 (vandetanib) 100mg
RxNorm normalized name: vandetanib 100 MG
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily oral tablet
Trial: NCT00506051
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intravenous infusion
Trial: NCT00506051
Drug: ZD6474 (vandetanib) 300mg
RxNorm normalized name: vandetanib 300 MG
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04116502
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg of ruxolitinib twice daily (bd)
Trial: NCT04116502
Drug: Hydroxycarbamide
RxNorm normalized name: Hydroxycarbamide
DrugBank: Hydroxyurea (DB01005)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Via standard hospital mechanisms
Trial: NCT04116502
Drug: Interferon-Alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Any formulation, via standard hospital mechanisms
Trial: NCT01455428
Drug: Lyrica (pregabalin)
RxNorm normalized name: pregabalin Oral Capsule [Lyrica]
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsule, 300 mg/d, BID, 8 weeks treatment
Trial: NCT00301067
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patient will receive temozolomide in capsule form by mouth on Days 2-8 and 16-22 of each 28 study treatment cycle
Trial: NCT01062451
Drug: Perindopril
RxNorm normalized name: Perindopril
DrugBank: Perindopril (DB00790)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg taken orally from days 0 through 7.
Trial: NCT01062451
Drug: Candesartan
RxNorm normalized name: Candesartan
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg taken orally from days 0 through 7.
Trial: NCT01269541
Drug: Mupirocin
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical in the nose 3 times daily for 5 days
Trial: NCT03969706
Drug: Abemaciclib 200 MG
RxNorm normalized name: abemaciclib 200 MG
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will be treated with abemaciclib 200mg by mouth once every 12 hours. Dosing will be continuous and administered on a 28-day cycle
Trial: NCT00151762
Drug: Colesevelam hydrochloride
RxNorm normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00026468
Drug: exisulind
RxNorm normalized name: Exisulind
DrugBank: Exisulind (DB06246)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04004507
Drug: Phentolamine Mesylate Ophthalmic Solution 1%
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Sterile Ophthalmic Solution
Trial: NCT01806337
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Consolidation after CHOP induction
Trial: NCT02200822
Drug: RAAS blockers
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RAAS blockers (combination of ACE-I/ARB and a mineralocorticoid receptor antagonist)
Trial: NCT02756624
Drug: AC-170 Vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02783586
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ml of bupivacaine with adrenaline
Trial: NCT03588572
Drug: Venlafaxine hydrochloride capsules
RxNorm normalized name: Venlafaxine Hydrochloride
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation(the first day after randomization), each containing venlafaxine 75mg, 1 capsule per day, until 4 weeks after randomization
Trial: NCT01058174
Drug: micafungin
RxNorm normalized name: Micafungin
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT01058174
Drug: fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT01058174
Drug: liposomal amphotericin B
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT01058174
Drug: caspofungin
RxNorm normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT00478972
Drug: Rimonabant
RxNorm normalized name: Rimonabant
DrugBank: Rimonabant (DB06155)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tablet, oral administration
Trial: NCT03830918
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03830918
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01729598
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: generic valproic acid tablets packaged in placebo-matched capsules.
Trial: NCT00387660
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Trial: NCT00387660
Drug: irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Trial: NCT02126904
Drug: IVA group
RxNorm normalized name: Iva axillaris pollen
DrugBank: Iva axillaris pollen (DB10764)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01316302
Drug: Pristiq
RxNorm normalized name: Pristiq
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flexible dose, 50-100mg QD, for 12 weeks.
Trial: NCT00789737
Drug: Welchol
RxNorm normalized name: Welchol
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Welchol 625mg tablets
Trial: NCT01676415
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily~If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead~Antihistamines if an appropriate history of atopy is obtained~Systemic prednisone: Starting dose of 40mg for five days followed by a taper decreasing by 10mg every 5 days~Following completion of the oral corticosteroid: Course of topical mometasone until the end of the study
Trial: NCT03520660
Drug: Epclusa
RxNorm normalized name: Epclusa
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: sofosbuvir/velapatasvir combination (Epclusa)
Trial: NCT00443430
Drug: methotrexate - etanercept - prednisolone arm
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus etanercept 0.8 mg/kg given by sub cutaneous injection once per week, plus prednisolone, by mouth daily with decreasing dose tapered over 16 weeks.
Trial: NCT00184912
Drug: Technetium-TC99m-labeled Annexin A5
RxNorm normalized name: TECHNETIUM TC99M TETROFOSMIN
DrugBank: Tetrofosmin (DB11180)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04652492
Drug: Tislelizumab in combination with cTACE
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demanded cTACE in combined with tislelizumab (200mg q3w ivgtt on day 4 of each 21-day cycle)
Trial: NCT00053846
Drug: buspirone hydrochloride
RxNorm normalized name: Buspirone Hydrochloride
DrugBank: Buspirone (DB00490)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose of buspirone will be 10 mg taken by mouth at bedtime for 3 days, then twice each day, in the morning and at bedtime for the remainder of the 28 day study period
Trial: NCT01168804
Drug: bendamustine plus bortezomib plus dexamethasone
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bendamustine 70 mg/m2 on days 1+4 Velcade 1.3 mg/m2 on days 1,4,8,11 Dexamethasone 20 mg on days 1,4,8 and 11 Repeated every 4 weeks
Trial: NCT01663740
Drug: Valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive valganciclovir 900 milligrams (mg) orally once daily for up to a maximum of 200 days post-transplant.
Trial: NCT03837756
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03837756
Drug: Lefitolimod
RxNorm normalized name: Lefitolimod
DrugBank: Lefitolimod (DB15061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A TLR9 agonist administered s.c. once weekly for 8 weeks.
Trial: NCT04624893
Drug: Polatuzumab Vedotin-Piiq
RxNorm normalized name: polatuzumab vedotin-piiq
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive a total of six cycles of Pola in combination with rituximab and bendamustine or in combination with only rituximab. A cycle is typically 21 days for DLBCL.
Trial: NCT01676415
Drug: Topical mometasone
RxNorm normalized name: mometasone Topical Cream
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily~If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead~Antihistamines if an appropriate history of atopy is obtained~Standing course of topical mometasone at the standard dose of 2 sprays to each nostril once daily and will remain on the topical mometasone until the end of the study.
Trial: NCT03855917
Drug: Sofosbuvir 400mg [Sovaldi]
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Four weeks.
Trial: NCT03855917
Drug: Glecaprevir/pibrentasvir (300mg/120mg)
DrugBank: Pibrentasvir (DB13878)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Four weeks.
Trial: NCT04292119
Drug: Lorlatinib
RxNorm normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lorlatinib will be taken orally once daily for 28 days when combined with crizotinib or binimetinib. Lorlatinib will be taken orally once daily for 21 days when combined with TNO155.~Crizotinib taken orally twice daily for 28 days.
Trial: NCT04292119
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib will be taken orally twice daily for 28 days.~Binimetnib taken orally twice daily for 28 days.
Trial: NCT04292119
Drug: Binimetinib
RxNorm normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Binimetinib will be taken orally twice daily for 28 days.
Trial: NCT04292119
Drug: TNO155
RxNorm normalized name: SHP2 inhibitor TNO155
DrugBank: Batoprotafib (DB19137)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNO155 will be taken orally once daily for 14 days.
Trial: NCT03008590
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 4.5 mg capsule each evening
Trial: NCT00829166
Drug: Trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
Trial: NCT00829166
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
Trial: NCT01968044
Drug: Gemigliptin
RxNorm normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01968044
Drug: Placebo to Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02084134
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5mg every 6 hours for a total of four doses
Trial: NCT01555463
Drug: Azelaic acid foam, 15% (BAY39-6251)
DrugBank: Azelaic acid (DB00548)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azelaic acid twice daily topical application
Trial: NCT01555463
Drug: Vehicle foam
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily topical application
Trial: NCT04436510
Drug: Verdiperstat
RxNorm normalized name: Verdiperstat
DrugBank: Verdiperstat (DB12440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Verdiperstat~Administration: Oral~Dose: 600mg twice daily
Trial: NCT01728272
Drug: blood concentration of metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: measure blood concentration of metoprolol
Trial: NCT02154269
Drug: Treatment with G-CSF (Granulocyte colony stimulating factor)
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will be randomly assigned to receive treatment with G-CSF (10mg/kg/day) for five days, during 4 cicles.
Trial: NCT00841295
Drug: Parenteral supplementation with sterile water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral supplementation with an equivalent volume of sterile water
Trial: NCT01649284
Drug: afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 40, 30, and 20 mg film-coated tablets
Trial: NCT02332031
Drug: Sorafenib (Nexavar, BAY43-9006)
RxNorm normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 400 mg orally on Period 1 Day 1 and Period 2 Day 11
Trial: NCT00830427
Drug: PF-00610355
RxNorm normalized name: PF-00610355
DrugBank: PF-00610355 (DB11871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mcg, QD, dry powder inhaler
Trial: NCT00830427
Drug: PF - 00610355
RxNorm normalized name: PF-00610355
DrugBank: PF-00610355 (DB11871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mcg, QD, dry powder inhaler
Trial: NCT02018055
Drug: Aspirin+Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin+ Ticagrelor after 1month of standard DAPT (Aspirin+Ticagrelor)
Trial: NCT02018055
Drug: Aspirin+Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Aspirin+ Clopidogrel after 1month of standard DAPT (Aspirin+Ticagrelor)
Trial: NCT00830427
Drug: PF - 00610355
RxNorm normalized name: PF-00610355
DrugBank: PF-00610355 (DB11871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mcg, QD, dry powder inhaler
Trial: NCT00607646
Drug: Dehydroepiandrosterone
RxNorm normalized name: Dehydroepiandrosterone
DrugBank: Prasterone (DB01708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo tablets or tablets containing DHEA will be given orally before each hyperinsulinemic clamps on day 1 (x 2). Placebo tablets or tablets containing DHEA will be given orally before Day 2 hyperinsulinemic hypoglycemic clamp x 1.
Trial: NCT01879748
Drug: Rasagiline
RxNorm normalized name: Rasagiline
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each subject will be enrolled into 1 of 4 cohorts:~* cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~* rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~* placebo (8 Japanese and 8 Caucasian subjects)
Trial: NCT01205984
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled in the study were given either oral amoxicillin/clavulanate (AMX/C) or metylprednisolone (MP) (group MP) or AMX/C and placebo (group P) twice daily using a random allocation chart based on a table of random numbers. Oral AMX/C was administered 45/6.4 mg/kg/d (maximum 2000/285 mg/d) for 30 days for both groups. Oral MP was administered for the first 15 days: 1 mg/kg/d (maximum 40 mg/d) for 10 days, 0.75 mg/kg/d for 2 days, 0.5 mg/kg/d for 2 days, and 0.25 mg/kg/d for 1 day. Placebo tablets contained lactose and were of same size and color as MP tablets.
Trial: NCT02568826
Drug: 3-glycosyl-3-Odemethylthiocolchicine derivative
RxNorm normalized name: 3-oxoandrosten (4) derivatives
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IDN 5243 is a new muscle relaxant molecule. This molecule has showed significant anti-inflammatory activity by intraperitoneal route at 10 mg/kg in both carrageenan induced oedema and granuloma tests. IDN 5243 is a new 3-glycosyl-3-Odemethylthiocolchicine derivative endowed with muscle-relaxant, anti-inflammatory and analgesic activities. The primary packaging of test formulation will be a glass vial containing a solution of IDN 5243, 4 mg/ 1 mL. The secondary package will correspond to the patient's kit and will be a box containing ten (10) vials. The box label will be provided with a tear-off label.
Trial: NCT00003667
Drug: dexrazoxane hydrochloride
RxNorm normalized name: Dexrazoxane Hydrochloride
DrugBank: Dexrazoxane (DB00380)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003667
Drug: disaccharide tripeptide glycerol dipalmitoyl
RxNorm normalized name: Disaccharide tripeptide glycerol dipalmitoyl
DrugBank: Disaccharide tripeptide glycerol dipalmitoyl (DB15423)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003667
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03485365
Drug: Placebo matching to GSK3858279 (SC or IV)
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Placebo will be available as sodium chloride solution to be administered via SC or IV route.
Trial: NCT03762850
Drug: sparsentan
RxNorm normalized name: SPARSENTAN
DrugBank: Sparsentan (DB12548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target dose of 400 mg daily
Trial: NCT03762850
Drug: irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Target dose of 300 mg daily
Trial: NCT03762850
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Target dose of 10 mg daily